利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.035 秒)

    Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
    13.
    发明申请
    Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety 审中-公开
    用于治疗抑郁和焦虑的血清素转运蛋白（SERT）抑制剂

    公开(公告)号：US20070129419A1

    公开(公告)日：2007-06-07

    申请号：US11603515

    申请日：2006-11-22

    申请人： Christophe Grundschober ,  Torsten Hoffmann ,  Andreas Koblet ,  Patrick Schnider

    发明人： Christophe Grundschober ,  Torsten Hoffmann ,  Andreas Koblet ,  Patrick Schnider

    IPC分类号： A61K31/40 ,  C07D207/04

    CPC分类号： C07D207/08 ,  C07D207/09

    摘要： The present invention relates to cis-derivatives of formula wherein R1, R2, and R3 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors). By virtue of their efficacy as SERT inhibitors, the compounds of the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.

    摘要翻译： 本发明涉及下式的顺式衍生物，其中R 1，R 2，R 3和R 3如本文所定义，并且与药学上可接受的酸 其加成盐。 式I化合物是5-羟色胺转运蛋白（SERT抑制剂）的良好抑制剂。 由于其作为SERT抑制剂的功效，本发明的化合物特别可用于治疗CNS紊乱和精神病，特别是治疗或预防抑郁状态和/或治疗焦虑症。

    NK-1 receptor antagonists
    16.
    发明授权
    NK-1 receptor antagonists 有权
    NK-1受体拮抗剂

    公开(公告)号：US07211579B2

    公开(公告)日：2007-05-01

    申请号：US11376042

    申请日：2006-03-15

    申请人： Christoph Funk ,  Torsten Hoffmann ,  Andreas Koblet

    发明人： Christoph Funk ,  Torsten Hoffmann ,  Andreas Koblet

    IPC分类号： A61K31/496 ,  C07D213/75 ,  C07D401/04

    CPC分类号： C07D213/75

    摘要： The present invention relates to compounds of formula I wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.

    摘要翻译： 本发明涉及式Ⅰ化合物，其中R是甲基; 并且R 1是4-甲基-4-氧 - 哌嗪-1-基; 或R是CH 2 OH，R 1是4-甲基 - 哌嗪-1-基，或是4-甲基-4-氧 - 哌嗪-1-基; 和其药学上可接受的酸加成盐，用于治疗NK-1受体相关疾病，例如抑郁症，帕金森病，阿尔茨海默病，焦虑症，呕吐和疼痛。

    NK-1 receptor antagonists
    17.
    发明申请
    NK-1 receptor antagonists 有权
    NK-1受体拮抗剂

    公开(公告)号：US20060217393A1

    公开(公告)日：2006-09-28

    申请号：US11376042

    申请日：2006-03-15

    申请人： Christoph Funk ,  Torsten Hoffmann ,  Andreas Koblet

    发明人： Christoph Funk ,  Torsten Hoffmann ,  Andreas Koblet

    IPC分类号： A61K31/496 ,  C07D403/04

    CPC分类号： C07D213/75

    摘要： The present invention relates to compounds of formula I wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.

    摘要翻译： 本发明涉及式Ⅰ化合物，其中R是甲基; 并且R 1是4-甲基-4-氧 - 哌嗪-1-基; 或R是CH 2 OH，R 1是4-甲基 - 哌嗪-1-基，或是4-甲基-4-氧 - 哌嗪-1-基; 和其药学上可接受的酸加成盐，用于治疗NK-1受体相关疾病，例如抑郁症，帕金森病，阿尔茨海默病，焦虑症，呕吐和疼痛。